Immunocore Holdings (IMCR) Other Non-Current Liabilities (2019 - 2025)

Immunocore Holdings (IMCR) has reported Other Non-Current Liabilities for 7 consecutive years, with $96.6 million the latest figure, recorded in Q3 2025.

• Quarterly Other Non-Current Liabilities rose 3113.71% year-over-year to $96.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $96.6 million (up 3113.71% YoY) and the FY2023 annual result came in at $978000.0, down 55.85% from the prior year.
• Other Non-Current Liabilities improved to $96.6 million in Q3 2025 per IMCR's latest filing, from $84.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for IMCR reached as high as $96.6 million in Q3 2025 and fell as low as $76836.6 in Q4 2021.
• A 5-year average of $22.9 million and a median of $2.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities tumbled 57.83% — and 2025, when it jumped 3919.15%.
• Year by year, Other Non-Current Liabilities stood at $76836.6 in 2021, then soared by 74.02% to $133713.8 in 2022, then surged by 631.41% to $978000.0 in 2023, then surged by 207.36% to $3.0 million in 2024, then soared by 3113.71% to $96.6 million in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $96.6 million, $84.0 million, and $62.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.